MX2021006005A - Composicion farmaceutica que comprende inhibidores de histona desacetilasa 6. - Google Patents

Composicion farmaceutica que comprende inhibidores de histona desacetilasa 6.

Info

Publication number
MX2021006005A
MX2021006005A MX2021006005A MX2021006005A MX2021006005A MX 2021006005 A MX2021006005 A MX 2021006005A MX 2021006005 A MX2021006005 A MX 2021006005A MX 2021006005 A MX2021006005 A MX 2021006005A MX 2021006005 A MX2021006005 A MX 2021006005A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
histone deacetylase
inhibitors
preventing
present
Prior art date
Application number
MX2021006005A
Other languages
English (en)
Inventor
Nina Ha
Daekwon Bae
Young Il Choi
Ju Young Song
Min Cheol Kim
Ji Yeon Baek
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2021006005A publication Critical patent/MX2021006005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

La presente invención se refiere a una composición farmacéutica para prevenir o tratar la enfermedad CMT, que comprende un inhibidor de la histona desacetilasa 6. La composición farmacéutica de acuerdo con la presente invención tiene actividad inhibidora de la histona desacetilasa 6 (HDAC6) y, por lo tanto, es eficaz para prevenir o tratar la enfermedad de CMT.
MX2021006005A 2018-11-23 2019-11-22 Composicion farmaceutica que comprende inhibidores de histona desacetilasa 6. MX2021006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180146732 2018-11-23
PCT/KR2019/016202 WO2020106119A1 (en) 2018-11-23 2019-11-22 Pharmaceutical composition comprising histone deacetylase 6 inhibitors

Publications (1)

Publication Number Publication Date
MX2021006005A true MX2021006005A (es) 2021-07-06

Family

ID=70773166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006005A MX2021006005A (es) 2018-11-23 2019-11-22 Composicion farmaceutica que comprende inhibidores de histona desacetilasa 6.

Country Status (11)

Country Link
US (1) US20220008414A1 (es)
EP (1) EP3883572A4 (es)
JP (1) JP2022513030A (es)
KR (1) KR20200061310A (es)
CN (1) CN113164470A (es)
AU (1) AU2019383277A1 (es)
BR (1) BR112021009921A2 (es)
CA (1) CA3119313A1 (es)
MX (1) MX2021006005A (es)
PH (1) PH12021551070A1 (es)
WO (1) WO2020106119A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CA3229931A1 (en) * 2021-08-31 2023-03-09 Nina Ha Compositions for preventing or treating charcot-marie-tooth disease (cmt)
KR20230160194A (ko) * 2022-05-16 2023-11-23 주식회사 종근당 특발성폐섬유증(ipf)의 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485365B1 (en) * 2002-03-13 2008-05-14 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
US8242175B2 (en) * 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
EP2133334A1 (en) * 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
AU2014260605B2 (en) * 2013-04-29 2016-07-14 Chong Kun Dang Pharmaceutical Corp. Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
KR101685639B1 (ko) * 2014-01-03 2016-12-12 주식회사 종근당 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2015137750A1 (en) * 2014-03-12 2015-09-17 Chong Kun Dang Pharmaceutical Corp. Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
MY197262A (en) * 2015-07-27 2023-06-08 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2016375634B2 (en) * 2015-12-22 2021-03-25 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
MX2019012674A (es) * 2017-04-26 2020-02-05 Univ Illinois Activadores de nrf y hif/inhibidores de hdac y metodos terapeuticos que usan estos.

Also Published As

Publication number Publication date
WO2020106119A1 (en) 2020-05-28
US20220008414A1 (en) 2022-01-13
CA3119313A1 (en) 2020-05-28
AU2019383277A1 (en) 2021-06-10
EP3883572A4 (en) 2022-11-30
BR112021009921A2 (pt) 2021-08-17
JP2022513030A (ja) 2022-02-07
PH12021551070A1 (en) 2021-12-06
CN113164470A (zh) 2021-07-23
KR20200061310A (ko) 2020-06-02
EP3883572A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
PH12021551070A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
MX2022002465A (es) Inhibidores de kras g12d.
MX2019011876A (es) Nuevos inhibidores de hdac6 selectivos.
EA201792673A1 (ru) 3-арил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
NZ750414A (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
PH12018501976A1 (en) Arginase inhibitors and their therapeutic applications
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
MX2019007346A (es) Inhibidores de histona deacetilasa.
PT3827004T (pt) Derivados da 4-(1,3,4-oxadiazol-2-il)piridin-2(1h)-ona como inibidores da histona desacetilase 6 (hdac6) para o tratamento de infeções e.g.
MD3664802T2 (ro) Inhibitori biciclici ai deacetilazei histonei
BR112017028139A2 (pt) inibidores de histona desacetilase
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2021000469A (es) Inhibidores biciclicos de las histona desacetilasas.
PH12018500096A1 (en) Mdm2 inhibitors for treating uveal melanoma
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
PH12021550660A1 (en) Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate